12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Votrient pazopanib: Phase III data

GlaxoSmithKline disclosed in its 1Q13 earnings that a double-blind, international Phase III trial in about 940 patients with epithelial ovarian, fallopian tube or primary peritoneal cancer that did not progress after first-line chemotherapy showed that once-daily 800 mg Votrient...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >